NeOnc Technologies Holdings

NTHI · NASDAQ

$2.77+$0.05 (+1.84%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $2.72

NTHI analyst rating

BuyConsensus of 4 analysts over the last 12 months. 100% rate it a buy.

Strong buy0
Buy4
Hold0
Underperform0
Sell0

12-month price target · 7 analysts

Average $16.67 (+501.7% upside)

Low: $13.13
Now: $2.77
High: $21.00

Upgrades and downgrades

The latest rating actions, newest first

NTHI analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Roth Capital	Sep 24, 2026	Initiates	Buy	$20.00	25%
BTIG	Sep 8, 2026	Maintains	Buy	$15.00	30%
BTIG	May 26, 2026	Maintains	Buy	$15.00	30%
Alliance Global Partners	May 19, 2026	Initiates	Buy	$13.00	0%
Maxim Group	May 18, 2026	Initiates	Buy	$20.00	27%
BTIG	Apr 24, 2026	Initiates	Buy	$15.00	30%

The case for and against

Updated Oct 15, 2026

Bull case

NeOnc Technologies Hldgs is supported by a differentiated CNS-delivery platform centered on Perillyl Alcohol, which both crosses the blood-brain barrier and enhances delivery of companion drugs, addressing a major bottleneck in brain-tumor therapy. Its lead assets, NEO100 and NEO212, have shown encouraging clinical signals including a 24% radiographic remission rate, 44% six-month PFS, 33% PFS-6 in a recurrent GBM study, and 3X CNS exposure versus temozolomide, while NEO212’s Phase 1 also defined a Phase 2 dose with clear activity in heavily pretreated patients. Financially, the company reported a Q1 net loss of $8.8M, normalized cash operating expenses of about $6.1M, and funding expected to last into September 2026, while its exclusive IP position includes 28 issued U.S. patents and 65 issued international patents.

Bear case

NeOnc Technologies Hldgs is a clinical-stage biotech with no commercial revenue and a heavy burn profile, underscored by a $14.2M net loss and $14.1M net operating loss in 2Q26 against just $2M in cash and equivalents, leaving little margin for setbacks. Its lead value driver, NEO212, still faces meaningful execution risk because the FDA-required capsule-to-tablet transition needs an in vivo relative bioavailability study and additional manufacturing work before confirmatory testing, adding timeline pressure and regulatory complexity. The bearish outlook is further supported by the inherent uncertainty of CNS drug delivery, competition in GBM, and the possibility that safety, tumor-location, or reimbursement issues could limit uptake even if early preclinical and Phase I signals remain encouraging.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.